Therapeutic vaccines in metastatic castration-resistant prostate cancer: Principles in clinical trial design

Expert Opinion on Biological Therapy

Volumn 10, Issue 1, 2010, Pages 19-28

  Madan, Ravi A ^a   Mohebtash, Mahsa ^a   Schlom, Jeffrey ^a   Gulley, James L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Clinical trial design; Immunotherapy; Prostate cancer; Therapeutic cancer vaccine

Indexed keywords

CANCER VACCINE; DOCETAXEL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROVENGE; PSA TRICOM; UNCLASSIFIED DRUG;

CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FOLLOW UP; HUMAN; METASTASIS; OVERALL SURVIVAL; PATIENT SELECTION; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; REVIEW;

CANCER VACCINES; CASTRATION; CLINICAL TRIALS AS TOPIC; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RESEARCH DESIGN;

EID: 72449127534     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590903321421     Document Type: Review

References (82)

1. Roehl KA, Han M, Ramos CG, et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004;172:910-914
2. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-974 (Pubitemid 28445094)
3. Zelefsky MJ, Chan H, Hunt M, et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 2006;176:1415-1419
4. Han M, Partin AW, Zahurak M, et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003;169:517-523
5. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005;294:238-244
6. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512
7. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-1520
8. Coffey DS, Isaacs JT. Prostate tumor biology and cell kinetics-theory. Urology 1981;17:40-53
9. Rhodes DR, Barrette TR, Rubin MA, et al. Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res 2002;62:4427-4433
10. Fong L, Small EJ. Immunotherapy for prostate cancer. Semin Oncol 2003;30:649-658
11. Chakraborty NG, Stevens RL, Mehrotra S, et al. Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation. Cancer Immunol Immunother 2003;52:497-505
12. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907-923
13. Madan RA, Gulley JL, Arlen PM. PSA-based vaccines for the treatment of prostate cancer. Expert Rev Vaccines 2006;5:199-209
14. Murphy GP, Elgamal AA, Su SL, et al. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer 1998;83:2259-2269
15. Wright GL Jr, Grob BM, Haley C, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996;48:326-334
16. Veeramani S, Yuan TC, Chen SJ, et al. Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer. Endocr Relat Cancer 2005;12:805-822
17. Vihko P, Virkkunen P, Henttu P, et al. Molecular cloning and sequence analysis of cDNA encoding human prostatic acid phosphatase. FEBS Lett 1988;236:275-281
18. Bera TK, Das S, Maeda H, et al. NGEP, a gene encoding a membrane protein detected only in prostate cancer and normal prostate. Proc Natl Acad Sci USA 2004;101:3059-3064
19. Kobayashi H, Nagato T, Oikawa K, et al. Recognition of prostate and breast tumor cells by helper T lymphocytes specific for a prostate and breast tumor-associated antigen, TARP. Clin Cancer Res 2005;11:3869-3878
20. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000;18:3894-3903
21. Rini BI. Technology evaluation: APC-8015, dendreon. Curr Opin Mol Ther 2002;4:76-79
22. Patel PH, Kockler DR. Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. Ann Pharmacother 2008;42:91-98
23. Hodge JW, Sabzevari H, Yafal AG, et al. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res 1999;59:5800-5807
24. Correale P, Walmsley K, Nieroda C, et al. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst 1997;89:293-300
25. Correale P, Walmsley K, Zaremba S, et al. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. J Immunol 1998;161:3186-3194
26. Madan RA, Arlen PM, Mohebtash M, et al. Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs 2009;18:1001-1011
27. Essajee S, Kaufman HL. Poxvirus vaccines for cancer and HIV therapy. Expert Opin Biol Ther 2004;4:575-588
28. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA 1996;93:11341-11348
29. Hodge JW, Grosenbach DW, Rad AN, et al. Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules. Vaccine 2001;19:3552-3567
30. Zhu M, Terasawa H, Gulley J, et al. Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells. Cancer Res 2001;61:3725-3734
31. Palena C, Zhu M, Schlom J, Tsang KY. Human B cells that hyperexpress a triad of costimulatory molecules via avipox-vector infection: an alternative source of efficient antigen-presenting cells. Blood 2004;104:192-199
32. Ward JE, McNeel DG. GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer. Expert Opin Biol Ther 2007;7:1893-1902
33. Cell Genesys Takeda Announce Termination of Collaboration Agreement for GVAX Immunotherapy for Prostate Cancer. Cell Genesys press release. San Francisco, California and Osaka, Japan. 2008. Available at: http://phx. corporate-ir. net/preview/phoenix.zhtml?c=98399& p=irol-newsArticle&ID= 1231960& highlight= [Last accessed 18 September 2009]
34. Eaton JD, Perry MJ, Nicholson S, et al. Allogeneic whole-cell vaccine: a phase I/IIstudy in men with hormone-refractory prostate cancer. BJU Int 2002;89:19-26
35. von Mehren M, Arlen P, Gulley J, et al. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res 2001;7:1181-1191
36. Fu T, Shen Y, Fujimoto S. Tumor-specific CD4+ suppressor T-cell clone capable of inhibiting rejection of syngeneic sarcoma in A/J mice. Int J Cancer 2000;87:680-687
37. Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004;34:336-344
38. Piccirillo CA, Shevach EM. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 2001;167:1137-1140
39. Woo EY, Yeh H, Chu CS, et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002;168:4272-4276
40. Teicher BA. Transforming growth factor-beta and the immune response to malignant disease. Clin Cancer Res 2007;13:6247-6251
41. Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in immune suppression and cancer. Curr Cancer Drug Targets 2007;7:31-40
42. Madan RA, Gulley JL, Schlom J, et al. Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res 2008;14:4526-4531
43. Small E, Schellhammer P, Higano C, et al. Immunotherapy (APC8015) for androgen independent prostate cancer (AIPC): final survival data from a phase 3 randomized placebo-controlled trial [abstract]. ASCOProstate Cancer Symposium 2005;64
44. Madan R, Gulley J, Dahut W, et al. Overall survival (OS) analysis of a phase II study using a pox viral-based vaccine, PSA-TRICOM, in the treatment of metastatic, castrate-resistant prostate cancer (mCRPC): implications for clinical trial design [abstract]. ASCO Meeting Abstracts 2008;3005
45. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-1597
46. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294:433-439
47. Flutamide with or without vaccine therapy in treating patients with nonmetastatic prostate cancer. Clinical trials.gov Bethesda, Maryland, National Institutes of Health 2009; Available at: http://www. clinicaltrials.gov/ct2/ show/ NCT00450463?term=gulley&rank=10 [Last accessed 18 September 2009]
48. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003;21:1232-1237
49. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24:3089-3094
50. Small E, Rini B, Higano C, et al. randomized, placebo-controlled phase III trial of APC8015 in patients with androgen-independent prostate cancer (AiPCa) [abstract]. ASCO Annual Meeting 2003;1534
51. Higano C, Saad F, Somer B, et al. A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC) [abstract]. ASCO Genitourinary Cancers Symposium 2009;LBA150
52. Schuster S, Neelapu S, Gause B, et al. Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results. J Clin Oncol 2009;27(18S):2
53. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216 (Pubitemid 30099779)
54. Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 2006;42:1031-1039
55. Gulley JL, Arlen PM, Tsang KY, et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res 2008;14:3060-3069
56. Jones RL, Cunningham D, Cook G, Ell PJ. Tumour vaccine associated lymphadenopathy and false positive positron emission tomography scan changes. Br J Radiol 2004;77:74-75
57. Loveland BE, Zhao A, White S, et al. Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res 2006;12:869-877
58. Kantoff P, Glode L, Tannenbaum S, et al. Randomized, double-blind, vector-controlled study of targeted immunotherapy in patients (pts) with hormone-refractory prostate cancer (HRPC) [abstract]. J Clin Oncol 2006;24(18S):2501
59. PROSTVAC-promising Phase II results lead to Phase III in 2010. Kvistgar̊d, Denmark: Bavarian Nordic 2009; Available at: http://www.bavarian-nordic.com/ prostvac [Last accessed 18 September 2009]
60. Cellular, Tissue and Gene Therapies Advisory Committee: Sipuleucel-T Briefing Document. Bethesda Maryland, USFDA, 2007; Available at: http://www.fda.gov/ohrms/dockets/ac/07/ briefing/2007-4291B1-01.pdf [Last accessed 18 September 2009]
61. AUA Late-Breaking Science Forum: Review of the Provenge TrialAccessed: May 2009; Available from: http://www. aua2009.org/program/lbsciforum.asp
62. Garnett CT, Schlom J, Hodge JW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res 2008;14:3536-3544
63. Gribben JG, Ryan DP, Boyajian R, et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res 2005;11:4430-4436
64. Antonia SJ, Mirza N, Fricke I, et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 2006;12:878-8765.
65. Petrylak D. Defining the optimal role of immunotherapy and chemotherapy: advanced prostate cancer patients who receive sipuleucel-T (Provenge) followed by docetaxel derive greatest survival benefit [abstract]. Chemotherapy Foundation Symposium 14th Annual Meeting 2006;N/A
66. Higano CS, Corman JM, Smith DC, et al. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 2008;113:975-984
67. GVAX Immunotherapy for Prostate Cancer. San Francisco, California: Cell Genesys 2009. Available at: http://www. cellgenesys.com/view.cfm/20/ GVAXImmunotherapy- for-Prostate-Cancer [Last accessed 18 September 2009]
68. Small E, Demkow T, Gerritsen W, et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC) [abstract]. ASCO Genitourinary Cancers Symposium 2009;7
69. Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151-1164
70. Morse MA, Clay TM, Mosca P, Lyerly HK. Immunoregulatory T cells in cancer immunotherapy. Expert Opin Biol Ther 2002;2:827-834
71. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000;101:455-458
72. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-949
73. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/ regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005;102:18538-18543
74. Kawaida H, Kono K, Takahashi A, et al. Distribution of CD4+CD25high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer. J Surg Res 2005;124:151-157
75. Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4+CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;61:4766-4772
76. Ganesh BB, Cheatem DM, Sheng JR, et al. GM-CSF-induced CD11c+CD8a- dendritic cells facilitate Foxp3+ and IL-10+ regulatory T cell expansion resulting in suppression of autoimmune thyroiditis. Int Immunol 2009;21:269-282
77. Chai JG, Coe D, Chen D, et al. In vitro expansion improves in vivo regulation by CD4+CD25+ regulatory T cells. J Immunol 2008;180:858-869
78. Gaudreau S, Guindi C, Menard M, et al. Granulocyte-macrophage colony-stimulating factor prevents diabetes development in NOD mice by inducing tolerogenic dendritic cells that sustain the suppressive function of CD4+CD25+ regulatory T cells. J Immunol 2007;179:3638-3647
79. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182
80. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-2648
81. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-726
82. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792